A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine release_xouv2l76drdlfigwtgy6mklxey

by Laura Q. Chow, Rafael Santana-Davila, Austin Pantel, Mara Roth, Leslie N. Anderson, Alan Failor, Robert Doot, David Mankoff

Published in PLoS ONE by Public Library of Science (PLoS).

2017   Volume 12, e0178325

Archived Files and Locations

application/pdf  3.8 MB
file_znbqi7cakjhyxckrw6fcnaz7je
web.archive.org (webarchive)
journals.plos.org (publisher)
application/pdf  1.7 MB
file_7vtvyz6c3jbmlpcezpgwhsakqy
web.archive.org (webarchive)
pdfs.semanticscholar.org (aggregator)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2017-06-29
Language   en ?
DOI  10.1371/journal.pone.0178325
PubMed  28662033
PMC  PMC5490965
Wikidata  Q33852864
Container Metadata
Open Access Publication
In DOAJ
Not in Keepers Registry
ISSN-L:  1932-6203
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 14c88fc2-b3b0-46ca-b06a-0535dccc024c
API URL: JSON